{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:55:37Z","timestamp":1766022937787,"version":"3.48.0"},"reference-count":39,"publisher":"e-Century Publishing Corporation","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/wkfj4968","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T04:23:58Z","timestamp":1738902238000},"page":"674-684","source":"Crossref","is-referenced-by-count":0,"title":["Clinical effectiveness of Anlotinib combined with PD-1 inhibitors in treating advanced non-small-cell lung carcinoma"],"prefix":"10.62347","volume":"17","author":[{"given":"Zhaoqing","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"RL","year":"2020","unstructured":"Siegel RL, Miller KD and Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7-30.","journal-title":"CA Cancer J Clin"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-021-01121-2","article-title":"Targeted therapy in advanced non-small cell lung cancer: current advances and future trends","volume":"14","author":"Majeed","year":"2021","unstructured":"Majeed U, Manochakian R, Zhao Y and Lou Y. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. J Hematol Oncol 2021; 14: 108.","journal-title":"J Hematol Oncol"},{"doi-asserted-by":"publisher","unstructured":"Oser MG, Niederst MJ, Sequist LV and Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol 2015; 16: e165-172.","key":"ref2","DOI":"10.1016\/S1470-2045(14)71180-5"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"RL","year":"2018","unstructured":"Siegel RL, Miller KD and Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018; 68: 7-30.","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"506","DOI":"10.21037\/tlcr.2020.03.40","article-title":"Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival","volume":"10","author":"Casal-Mourino","year":"2021","unstructured":"Casal-Mourino A, Ruano-Ravina A, Lorenzo-Gonzalez M, Rodriguez-Martinez A, Giraldo-Osorio A, Varela-Lema L, Pereiro-Brea T, Barros-Dios JM, Valdes-Cuadrado L and Perez-Rios M. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res 2021; 10: 506-518.","journal-title":"Transl Lung Cancer Res"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1038\/s41467-021-22801-0","article-title":"Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer","volume":"12","author":"Wu","year":"2021","unstructured":"Wu F, Fan J, He Y, Xiong A, Yu J, Li Y, Zhang Y, Zhao W, Zhou F, Li W, Zhang J, Zhang X, Qiao M, Gao G, Chen S, Chen X, Li X, Hou L, Wu C, Su C, Ren S, Odenthal M, Buettner R, Fang N and Zhou C. Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nat Commun 2021; 12: 2540.","journal-title":"Nat Commun"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.lungcan.2019.10.019","article-title":"Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model","volume":"139","author":"Moldaver","year":"2020","unstructured":"Moldaver D, Hurry M, Evans WK, Cheema PK, Sangha R, Burkes R, Melosky B, Tran D, Boehm D, Venkatesh J, Walisser S, Orava E and Grima D. Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model. Lung Cancer 2020; 139: 185-194.","journal-title":"Lung Cancer"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.7150\/jca.55936","article-title":"Prognostic nutritional index identifies risk of early progression and survival outcomes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors","volume":"12","author":"Liu","year":"2021","unstructured":"Liu N, Jiang A, Zheng X, Fu X, Zheng H, Gao H, Wang J, Liang X, Tian T, Ruan Z and Yao Y. Prognostic nutritional index identifies risk of early progression and survival outcomes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors. J Cancer 2021; 12: 2960-2967.","journal-title":"J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.21037\/tlcr-21-43","article-title":"Prognostic value of baseline and change in neutrophil-to-lymphocyte ratio for survival in advanced non-small cell lung cancer patients with poor performance status receiving PD-1 inhibitors","volume":"10","author":"Chen","year":"2021","unstructured":"Chen S, Li R, Zhang Z, Huang Z, Cui P, Jia W, Zhang S, Tao H, Wang L, Li X, Wang J, Ma J, Liu Z, Huang D, Zheng X, Saito Y, Ichiki Y and Hu Y. Prognostic value of baseline and change in neutrophil-to-lymphocyte ratio for survival in advanced non-small cell lung cancer patients with poor performance status receiving PD-1 inhibitors. Transl Lung Cancer Res 2021; 10: 1397-1407.","journal-title":"Transl Lung Cancer Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/cas.13536","article-title":"Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor","volume":"109","author":"Xie","year":"2018","unstructured":"Xie C, Wan X, Quan H, Zheng M, Fu L, Li Y and Lou L. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci 2018; 109: 1207-1219.","journal-title":"Cancer Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","article-title":"Effect of Anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial","volume":"4","author":"Han","year":"2018","unstructured":"Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, Yu H, Zhao Y, Chen W, Luo Y, Wu L, Wang X, Pirker R, Nan K, Jin F, Dong J, Li B and Sun Y. Effect of Anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol 2018; 4: 1569-1575.","journal-title":"JAMA Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11912-015-0448-y","article-title":"The role of anti-angiogenesis in non-small-cell lung cancer: an update","volume":"17","author":"Villaruz","year":"2015","unstructured":"Villaruz LC and Socinski MA. The role of anti-angiogenesis in non-small-cell lung cancer: an update. Curr Oncol Rep 2015; 17: 26.","journal-title":"Curr Oncol Rep"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.2147\/CMAR.S249678","article-title":"A trial of the safety and efficacy of chemotherapy plus Anlotinib vs chemotherapy alone as second- or third-line salvage treatment for advanced non-small cell lung cancer","volume":"12","author":"Wang","year":"2020","unstructured":"Wang HY, Chu JF, Zhao Y, Tang H, Wang LL, Zhou MQ, Yan Z, Liu YY and Yao ZH. A trial of the safety and efficacy of chemotherapy plus Anlotinib vs chemotherapy alone as second- or third-line salvage treatment for advanced non-small cell lung cancer. Cancer Manag Res 2020; 12: 3827-3834.","journal-title":"Cancer Manag Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"100788","DOI":"10.1016\/j.lanepe.2023.100788","article-title":"Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis","volume":"36","author":"Kastner","year":"2024","unstructured":"Kastner A, Kron A, van den Berg N, Moon K, Scheffler M, Schillinger G, Pelusi N, Hartmann N, Rieke DT, Stephan-Falkenau S, Schuler M, Wermke M, Weichert W, Klauschen F, Haller F, Hummel HD, Sebastian M, Gattenlohner S, Bokemeyer C, Esposito I, Jakobs F, von Kalle C, Buttner R, Wolf J and Hoffmann W. Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis. Lancet Reg Health Eur 2024; 36: 100788.","journal-title":"Lancet Reg Health Eur"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1089\/thy.2022.0115","article-title":"Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial","volume":"32","author":"Busaidy","year":"2022","unstructured":"Busaidy NL, Konda B, Wei L, Wirth LJ, Devine C, Daniels GA, DeSouza JA, Poi M, Seligson ND, Cabanillas ME, Sipos JA, Ringel MD, Eisfeld AK, Timmers C and Shah MH. Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial. Thyroid 2022; 32: 1184-1192.","journal-title":"Thyroid"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.3390\/jpm13111603","article-title":"Efficacy of low-level laser therapy for oral mucositis in hematologic patients undergoing transplantation: a single-arm prospective study","volume":"13","author":"Nishi","year":"2023","unstructured":"Nishi H, Horikoshi S, Ohta K, Yoshida T, Fukushima N, Oshita K, Munenaga S, Edahiro T, Ureshino H, Shigeishi H, Yoshioka Y, Konishi M, Ide N, Ogawa Y, Marukawa R, Shintani T, Ino N, Kajiya M, Kakimoto N, Ohge H, Ichinohe T and Kawaguchi H. Efficacy of low-level laser therapy for oral mucositis in hematologic patients undergoing transplantation: a single-arm prospective study. J Pers Med 2023; 13: 1603.","journal-title":"J Pers Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1055\/s-0039-1683932","article-title":"Age-specific reference intervals for PT, aPTT, fibrinogen and thrombin time for parturient women","volume":"119","author":"GM","year":"2019","unstructured":"Zhang GM, Zhang W and Zhang GM. Age-specific reference intervals for PT, aPTT, fibrinogen and thrombin time for parturient women. Thromb Haemost 2019; 119: 894-898.","journal-title":"Thromb Haemost"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/978-1-0716-2376-3_10","article-title":"Enzyme-linked immunosorbent assay (ELISA)","volume":"2508","author":"Tabatabaei","year":"2022","unstructured":"Tabatabaei MS and Ahmed M. Enzyme-linked immunosorbent assay (ELISA). Methods Mol Biol 2022; 2508: 115-134.","journal-title":"Methods Mol Biol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.4103\/njcp.njcp_1455_21","article-title":"Serum immunoglobulins, C-reactive protein, and trace element level in preeclamptic Nigerian subjects","volume":"25","author":"Nwatah","year":"2022","unstructured":"Nwatah AJ, Ugwu GO, Ugwu CE and Meludu SC. Serum immunoglobulins, C-reactive protein, and trace element level in preeclamptic Nigerian subjects. Niger J Clin Pract 2022; 25: 1405-1412.","journal-title":"Niger J Clin Pract"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13550-023-00976-5","article-title":"Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of (18)F-FDG PET\/CT and serum tumor markers CYFRA21-1 and SCC-Ag","volume":"13","author":"Jiang","year":"2023","unstructured":"Jiang M, Chen P, Guo X, Zhang X, Gao Q, Zhang J, Zhao G and Zheng J. Identification of EGFR mutation status in male patients with non-small-cell lung cancer: role of (18)F-FDG PET\/CT and serum tumor markers CYFRA21-1 and SCC-Ag. EJNMMI Res 2023; 13: 27.","journal-title":"EJNMMI Res"},{"doi-asserted-by":"publisher","unstructured":"Zitser J, Allen IE, Falgas N, Le MM, Neylan TC, Kramer JH and Walsh CM. Pittsburgh sleep quality index (PSQI) responses are modulated by total sleep time and wake after sleep onset in healthy older adults. PLoS One 2022; 17: e0270095.","key":"ref20","DOI":"10.1371\/journal.pone.0270095"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/pmrj.12741","article-title":"Translation of karnofsky performance status (KPS) for use in inpatient cancer rehabilitation","volume":"15","author":"McNair","year":"2023","unstructured":"McNair KM, Zeitlin D, Slivka AM, Lequerica AH and Stubblefield MD. Translation of karnofsky performance status (KPS) for use in inpatient cancer rehabilitation. PM R 2023; 15: 65-68.","journal-title":"PM R"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1007\/s00262-020-02641-5","article-title":"Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer","volume":"69","author":"Yang","year":"2020","unstructured":"Yang Y, Li L, Jiang Z, Wang B and Pan Z. Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer. Cancer Immunol Immunother 2020; 69: 2523-2532.","journal-title":"Cancer Immunol Immunother"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"659380","DOI":"10.3389\/fonc.2021.659380","article-title":"Real-world efficacy and safety of Anlotinib with and without immunotherapy in advanced non-small cell lung cancer","volume":"11","author":"Xiong","year":"2021","unstructured":"Xiong Q, Qin B, Xin L, Yang B, Song Q, Wang Y, Zhang S and Hu Y. Real-world efficacy and safety of Anlotinib with and without immunotherapy in advanced non-small cell lung cancer. Front Oncol 2021; 11: 659380.","journal-title":"Front Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/lctt.s444884","article-title":"Effectiveness and safety of Anlotinib combined with PD-1 blockades in patients with previously immunotherapy treated advanced non-small cell lung cancer: a retrospective exploratory study","volume":"15","author":"Dou","year":"2024","unstructured":"Dou XJ, Ma RY, Ren DW, Liu Q and Yan P. Effectiveness and safety of Anlotinib combined with PD-1 blockades in patients with previously immunotherapy treated advanced non-small cell lung cancer: a retrospective exploratory study. Lung Cancer (Auckl) 2024; 15: 29-40.","journal-title":"Lung Cancer (Auckl)"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.2147\/CMAR.S246000","article-title":"Efficacy and safety of Anlotinib in advanced non-small cell lung cancer: a real-world study","volume":"12","author":"Zhang","year":"2020","unstructured":"Zhang K, Ma X, Gao H, Wang H, Qin H, Yang S and Liu X. Efficacy and safety of Anlotinib in advanced non-small cell lung cancer: a real-world study. Cancer Manag Res 2020; 12: 3409-3417.","journal-title":"Cancer Manag Res"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.3390\/cancers12061619","article-title":"Systemic inflammation and activation of haemostasis predict poor prognosis and response to chemotherapy in patients with advanced lung cancer","volume":"12","author":"Moik","year":"2020","unstructured":"Moik F, Zochbauer-Muller S, Posch F, Pabinger I and Ay C. Systemic inflammation and activation of haemostasis predict poor prognosis and response to chemotherapy in patients with advanced lung cancer. Cancers (Basel) 2020; 12: 1619.","journal-title":"Cancers (Basel)"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.beha.2008.12.009","article-title":"Procoagulant mechanisms in tumour cells","volume":"22","author":"Falanga","year":"2009","unstructured":"Falanga A, Panova-Noeva M and Russo L. Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol 2009; 22: 49-60.","journal-title":"Best Pract Res Clin Haematol"},{"unstructured":"Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG and Degen JL. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 2002; 62: 6966-6972.","key":"ref28"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3390\/cancers11030316","article-title":"Tumor neovascularization and developments in therapeutics","volume":"11","author":"Katayama","year":"2019","unstructured":"Katayama Y, Uchino J, Chihara Y, Tamiya N, Kaneko Y, Yamada T and Takayama K. Tumor neovascularization and developments in therapeutics. Cancers (Basel) 2019; 11: 316.","journal-title":"Cancers (Basel)"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.7150\/ijbs.70958","article-title":"VEGF\/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer: targeting the tumor microenvironment","volume":"18","author":"Zhao","year":"2022","unstructured":"Zhao Y, Guo S, Deng J, Shen J, Du F, Wu X, Chen Y, Li M, Chen M, Li X, Li W, Gu L, Sun Y, Wen Q, Li J and Xiao Z. VEGF\/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer: targeting the tumor microenvironment. Int J Biol Sci 2022; 18: 3845-3858.","journal-title":"Int J Biol Sci"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3892\/etm.2021.10390","article-title":"FOXP3 facilitates the invasion and metastasis of non-small cell lung cancer cells through regulating VEGF, EMT and the Notch1\/Hes1 pathway","volume":"22","author":"Li","year":"2021","unstructured":"Li C, Wang H, Fang H, He C, Pei Y and Gai X. FOXP3 facilitates the invasion and metastasis of non-small cell lung cancer cells through regulating VEGF, EMT and the Notch1\/Hes1 pathway. Exp Ther Med 2021; 22: 958.","journal-title":"Exp Ther Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s12094-013-1020-6","article-title":"VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer","volume":"15","author":"Fleitas","year":"2013","unstructured":"Fleitas T, Martinez-Sales V, Vila V, Reganon E, Mesado D, Martin M, Gomez-Codina J, Montalar J and Reynes G. VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer. Clin Transl Oncol 2013; 15: 897-902.","journal-title":"Clin Transl Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"6477","DOI":"10.1007\/s13277-015-3338-x","article-title":"Platelet VEGF and serum TGF-beta1 levels predict chemotherapy response in non-small cell lung cancer patients","volume":"36","author":"BH","year":"2015","unstructured":"Fu BH, Fu ZZ, Meng W, Gu T, Sun XD and Zhang Z. Platelet VEGF and serum TGF-beta1 levels predict chemotherapy response in non-small cell lung cancer patients. Tumour Biol 2015; 36: 6477-6483.","journal-title":"Tumour Biol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1195426","DOI":"10.3389\/fonc.2023.1195426","article-title":"The multifaceted roles of matrix metalloproteinases in lung cancer","volume":"13","author":"Wei","year":"2023","unstructured":"Wei C. The multifaceted roles of matrix metalloproteinases in lung cancer. Front Oncol 2023; 13: 1195426.","journal-title":"Front Oncol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1159\/000369753","article-title":"GOLPH3 overexpression is closely correlated with poor prognosis in human non-small cell lung cancer and mediates its metastasis through upregulating MMP-2 and MMP-9","volume":"35","author":"Wang","year":"2015","unstructured":"Wang R, Ke ZF, Wang F, Zhang WH, Wang YF, Li SH and Wang LT. GOLPH3 overexpression is closely correlated with poor prognosis in human non-small cell lung cancer and mediates its metastasis through upregulating MMP-2 and MMP-9. Cell Physiol Biochem 2015; 35: 969-982.","journal-title":"Cell Physiol Biochem"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3390\/ijms23031240","article-title":"Role of periostin expression in non-small cell lung cancer: periostin silencing inhibits the migration and invasion of lung cancer cells via regulation of MMP-2 expression","volume":"23","author":"Ratajczak-Wielgomas K","year":"2022","unstructured":"Ratajczak-Wielgomas K, Kmiecik A and Dziegiel P. Role of periostin expression in non-small cell lung cancer: periostin silencing inhibits the migration and invasion of lung cancer cells via regulation of MMP-2 expression. Int J Mol Sci 2022; 23: 1240.","journal-title":"Int J Mol Sci"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.3390\/cancers15184648","article-title":"Angiogenesis in lung cancer: understanding the roles of growth factors","volume":"15","author":"Ngaha","year":"2023","unstructured":"Ngaha TYS, Zhilenkova AV, Essogmo FE, Uchendu IK, Abah MO, Fossa LT, Sangadzhieva ZD, D Sanikovich V, S Rusanov A, N Pirogova Y, Boroda A, Rozhkov A, Kemfang Ngowa JD, N Bagmet L and I Sekacheva M. Angiogenesis in lung cancer: understanding the roles of growth factors. Cancers (Basel) 2023; 15: 4648.","journal-title":"Cancers (Basel)"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s12272-022-01382-6","article-title":"Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer","volume":"45","author":"Choi","year":"2022","unstructured":"Choi SH, Yoo SS, Lee SY and Park JY. Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer. Arch Pharm Res 2022; 45: 263-279.","journal-title":"Arch Pharm Res"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/1\/ajtr0161340.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:50:44Z","timestamp":1766022644000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/1\/ajtr0161340.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/wkfj4968","relation":{},"ISSN":["1943-8141"],"issn-type":[{"type":"electronic","value":"1943-8141"}],"subject":[],"published":{"date-parts":[[2025]]}}}